By continuing to use our site, you consent to the processing of cookies, user data (location information, type and version of the OS, the type and version of the browser, the type of device and the resolution of its screen, the source of where the user came from, from which site or for what advertisement, language OS and Browser, which pages are opened and to which buttons the user presses, ip-address) for the purpose of site functioning, retargeting and statistical surveys and reviews. If you do not want your data to be processed, please leave the site.

The Voice of People With Breast Cancer


Our Voices Blog

Research Highlights from the European Society for Medical Oncology 2019 Conference

CBCN had the opportunity to join researchers, clinicians, manufacturers and other patients at this annual European conference to learn the latest insights and findings in cancer research. Here’s the research that we found most interesting as breast cancer patients:

  1. KEYNOTE 522 Trial – Early Stage Triple Negative Breast Cancer –  This phase 3 trial showed that using pembrolizumab, an immunotherapy, as neo-adjuvant treatment in early stage triple negative breast cancer increases the likelihood that patients will not have residual disease by the time they have surgery. For the patients who received pembrolizumab, their pathological complete response(pCR) was 65% compared with patients who were only given chemotherapy whose pCR was 51%. pCR has been a recognized indicator for overall survival. Read more HERE about the results of this clinical trial.
  2. KATE2 Trial – Advanced or Metastatic HER2-positive Breast Cancer. This phase 2 trial showed that adding atezolizumab to T-DM1 improved overall survival in patients, particularly those with PD-L1 expression. Learn more HERE about this immunotherapy for HER2-positive breast cancer. 
  3. MONARCH 2 trial – Advance or Metastatic HR-positive HER2-Negative Breast Cancer – Results from this phase 3 trial demonstrated that abemaciclib, a CDK4/6 inhibitor, in combination with fulvestrant improved overall survival by 9.4 months compared with fulvestrant alone. Read more HERE about the recent results from this trial.
  4. 2YoungPearl Study – Advanced or Metastatic HR-positive HER2-negative Breast Cancer – This study demonstrated that patient reported outcomes for quality of life were similar among patients who received capecitabine and those who received palbociclib plus exemestane. Read more about the study HERE.
  5. MONALEESA-3 Trial – Advance or Metastatic HR-positive HER2-negative Breast Cancer – This phase 3 trial demonstrated that ribociclib, a CDK4/6 inhibitor, plus fulvestrant increased overall survival in post-menopausal women. Learn more about the trial results HERE.

Photo by Alfons Taekema on Unsplash

The views and experiences expressed through personal stories on Our Voices Blog are those of the authors and their lived experiences. They do not necessarily reflect the position of the Canadian Breast Cancer Network. The information provided has not been medically reviewed and is not intended to be a substitute for professional medical advice. Always seek the guidance of your healthcare team when considering your treatment plans and goals.